Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
暂无分享,去创建一个
D. Grobbee | L. Rydén | J. Tardif | K. Malmberg | B. Neal | A. Lincoff | J. Buse | R. Henry | S. Nicholls | H. Wedel | G. Schwartz | R. Cannata | A. Weichert | Arlette Weichert
[1] Matthias Herz,et al. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study , 2014, BMC Nephrology.
[2] Joseph G Ibrahim,et al. Bayesian Meta‐Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes , 2012, Biometrics.
[3] Samy Suissa,et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study , 2012, BMJ : British Medical Journal.
[4] Natalie L. Catlett,et al. Comparative Transcriptional Network Modeling of Three PPAR-α/γ Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes , 2012, PloS one.
[5] T. Craven,et al. Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants , 2012, Diabetes Care.
[6] Armin Ruf,et al. Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors , 2012, ChemMedChem.
[7] T. Johnson,et al. Group art therapy as an adjunctive treatment for people with schizophrenia: multicentre pragmatic randomised trial , 2012, BMJ : British Medical Journal.
[8] N. Perico,et al. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. , 2011, International journal of cardiology.
[9] W. Bilker,et al. Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone , 2011, Diabetes Care.
[10] Deepak L. Bhatt,et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.
[11] D. Grobbee,et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.
[12] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.
[13] S. Mudaliar,et al. Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study , 2009, The Lancet.
[14] S. Schinner,et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .
[15] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[16] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[17] E. Tuzcu,et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.
[18] J. Alpert,et al. Universal definition of myocardial infarction. , 2007, European heart journal.
[19] Jeroen J. Bax,et al. Universal definition of myocardial infarction. , 2007 .
[20] Yoon K Loke,et al. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.
[21] A. Lincoff,et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.
[22] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[23] S. Haffner,et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.
[24] E. Braunwald,et al. Coronary heart disease Acute coronary syndromes and diabetes : is intensive lipid lowering beneficial ? Results of the PROVE IT-TIMI 22 trial , 2006 .
[25] Judith Wylie-Rosett,et al. Diet and Lifestyle Recommendations Revision 2006: A Scientific Statement From the American Heart Association Nutrition Committee , 2006, Circulation.
[26] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[27] E. Topol,et al. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.
[28] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[29] B. Staels,et al. Therapeutic roles of peroxisome proliferator-activated receptor agonists. , 2005, Diabetes.
[30] Alfonso T. Perez,et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. , 2005, Diabetes care.
[31] Shankar Subramaniam,et al. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes , 2004, Bioinform..
[32] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[33] Irene M. Stratton,et al. UK prospective diabetes study (UKPDS) , 2004, Diabetologia.
[34] N. Wareham,et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) , 2001, BMJ : British Medical Journal.
[35] 任艳,et al. 胰岛素增敏剂一Thiazolidinediones研究现状 , 2000 .
[36] Ames,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[37] O. Pedersen,et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.
[38] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[39] R. Holman,et al. U.K. Prospective Diabetes Study , 1996, Diabetes Care.
[40] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.